Information for healthcare professionals

Ozempic®. For adults with type 2 diabetes to improve glycemic control, when diet and exercise plus maximal tolerated metformin dose alone do not achieve adequate glycemic control.

For your patients: payment assistance and more

View Ozempic® A1C and weight data
(2° endpoint – Ozempic® is not indicated for weight reduction; data vs Trulicity®)

Watch this short video to learn more about Ozempic®

Chat with an eRep

If you want to learn more about Ozempic® or get samples, please use the form below. One of our eReps will get back to you as soon as possible.

Ask a medical question

If you have a specific question about Ozempic®, please email our Medical Information team using this form. Our team will get back to you as soon as possible.

Stay up to date

Ozempic®
Send me updates about (we won't contact you for any other reason and you can unsubscribe at any time):

Get the latest Ozempic® news

Recent Article

FOR YOUR PATIENTS: A SUPPORT PROGRAM AND APP

Introducing the Ozempic® Patient
Support Program and Ozempic® app

June 9, 2019

Our Ozempic® Patient Support Program is designed to help your patients at every stage of their treatment journey, as a compassionate, empathetic, and non-judgmental companion.

The program is designed to be multifaceted, helping your patients with motivation, goal setting, coping strategies, side effect management, emotional support, nutrition and the development of new routines and habits. It supports multiple learning styles through both coaching and peer learning opportunities provided via videos, infographics, guided tours, tips and tricks, and practical planning tools.

As part of this support program, your patients can download the Ozempic® app from Apple’s App Store or Google Play. The Ozempic® app is a support tool to help your patients get started and stay motivated and features Sema, a personal virtual companion. Sema can help your patients set regular dose reminders, schedule and prepare for appointments, track doses, track lifestyle changes and more. And Sema can generate PDF summaries for you to review as you help your patients along their treatment journey.

Recent Article

FOR YOUR PATIENTS: PAYMENT ASSISTANCE

The innoviCares free payment assistance card

June 9, 2019

We’re pleased to announce that innoviCares will now cover a portion of the cost* of Ozempic®. InnoviCares is a free payment assistance card that helps Canadians save money on select prescription medications and healthcare products. This payment assistance is sponsored by Novo Nordisk and is available to patients in all provinces and territories except Québec.

How do you help your patients benefit from innoviCares? Provide your patients with an innoviCares card or tear sheet and tell them to present the card and prescription when asking for the brand at pharmacy. Payment is automatic and coordinates seamlessly with your patients’ existing drug plans. Patients can also get a free card by visiting the innoviCares website.

*Depending on the benefit type and patient’s existing coverage, the card will pay all or some of the MLP, U&C mark up and/or dispensing fee. The innoviCares card is designed to provide the user with specific offerings. The user may still be responsible for additional costs not covered by their innoviCares card. Availability varies by province and territory. Individual programs may change or end at the manufacturer’s discretion.

Recent Article

FOR YOUR PATIENTS: NEW PEN FORMAT

One 4 mg pen instead of two 2 mg pens

June 9, 2019

We’re replacing the Ozempic® 2-pack that contains the two pens with 2 mg each (total of 4 mg/3 mL) with a 1-pack containing one pen of. It’s the same quantity of Ozempic®, just in one pen rather than two.

A1C AND WEIGHT DATA

See below for results from a trial comparing
Ozempic® with Trulicity® (dulaglutide)

October 26, 2018

The SUSTAIN 7 trial was an open-label, parallel-group, phase 3b trial done at 194 hospitals, clinical institutions or private practices in 16 countries. Eligible patients were aged 18 years or older and had type 2 diabetes with A1C 7.0–10.5% (53.0–91.0 mmol/mol) on metformin monotherapy. Patients were randomly assigned (1:1:1:1) by use of an interactive web-response system to once-a-week treatment with either Ozempic® 0.5 mg, Trulicity® 0.75 mg, Ozempic® 1 mg, or Trulicity® 1.5 mg subcutaneously. The primary endpoint was change from baseline in percentage A1C; the confirmatory secondary endpoint was change in bodyweight, both at week 40. The trial was powered for A1C non-inferiority (margin 0.4%) and bodyweight superiority.2

Highlights

At week 40, patients on Ozempic® 1 mg once weekly as an add-on to metformin experienced:
1.6% reduction in A1C from baseline (n=300, baseline 8.2%)1,2
5.8 kg weight loss from baseline (baseline 95.5 kg)1,2 (Ozempic® is not indicated for weight loss)

A1C

Demonstrated superior A1C reduction vs. Trulicity®, both as add-ons to metformin (p<0.0001)

At 40 weeks, patients on Ozempic® 0.5 mg once weekly saw a 1.4% reduction in A1C (n=301, baseline 8.3%) and patients on Ozempic® 1 mg once weekly experienced a 1.6% A1C reduction (n=300, baseline 8.2%) compared with patients on Trulicity® 0.75 mg who saw a 1.1% reduction (n=299, baseline 8.2%) and those on Trulicity® 1.5 mg who saw a 1.3% reduction (n=299, baseline 8.2%). Both Ozempic® 0.5 mg and Ozempic® 1 mg showed statistically significant reductions versus Trulicity® 0.75 mg and 1.5 mg, respectively (p<0.0001).1,2

Patients who achieved A1C of <7%
At 40 weeks, 65% of patients on Ozempic® 0.5 mg and 73% of patients on Ozempic® 1 mg once weekly achieved an A1C of <7.0%. 51% of patients on Trulicity® 0.75 mg and 63% on Trulicity® 1.5 mg achieved an A1C of <7.0%.1,2

Weight

Demonstrated weight reduction vs. Trulicity®, both as add-ons to metformin (2° endpoint, p<0.0001)

At 40 weeks, patients on Ozempic® 0.5 mg once weekly demonstrated weight loss of 4.2 kg (baseline 96.4 kg) while patients on Ozempic® 1 mg demonstrated weight loss of 5.8 kg (baseline 95.5 kg). Patients on Trulicity® 0.75 mg demonstrated weight loss of 2.1 kg (baseline 95.6 kg) while those on Trulicity® 1.5 mg demonstrated weight loss of 2.8 kg (baseline 93.4 kg). Ozempic® showed more than 2x the weight change versus Trulicity®, both as add-ons to metformin.1,2 (Ozempic® is not indicated for weight reduction.)

OZEMPIC® VERSUS JANUVIA® (SITAGLIPTIN)

See below for results from a trial
comparing Ozempic® with Januvia®

January 4, 2018

The SUSTAIN 2 trial was a 56-week, randomized, double-blind, double-dummy, active-controlled, parallel-group trial in which 1,231 patients were randomized 2:2:1:1 to Ozempic® 0.5 mg/Januvia® placebo, Ozempic® 1 mg/Januvia® placebo, Januvia®/Ozempic® 0.5 mg placebo or Januvia®/Ozempic® 1 mg placebo, all in combination with metformin (94%) and/or TZD (6%). Subjects continued pre-trial background medication throughout the entire trial. The primary objective was to compare the effect of once weekly dosing of 2 dose levels of Ozempic® vs. Januvia® 100 mg once daily on glycemic control after 56 weeks of treatment.

Demonstrated A1C reductions
At 56 weeks, patients on Ozempic® 0.5 mg once weekly saw a 1.3% reduction in A1C and those on Ozempic® 1 mg once weekly experienced a 1.5% reduction (both groups n=409, baseline 8.0%; p<0.0001) compared with patients on Januvia® 100 mg who saw a 0.7% reduction (n=407, baseline 8.2%). Both Ozempic® 0.5 mg and Ozempic® 1 mg showed statistically significant reductions versus Januvia®.1

Patients who achieved A1C of <7%
At 56 weeks, 66% of patients on Ozempic® 0.5 mg and 73% of patients on Ozempic® 1 mg once weekly achieved an A1C of <7.0%. 40% of patients on Januvia® 100 mg achieved an A1C of <7.0%.1

Demonstrated weight change
Patients on Ozempic® 0.5 mg once weekly demonstrated weight change of -4.2 kg (baseline 89.9 kg) while patients on Ozempic® 1 mg demonstrated weight change of -5.5 kg (baseline 89.2 kg). Patients on Januvia® 100 mg demonstrated weight change of -1.7 kg (baseline 89.3 kg).1 (Ozempic® is not indicated for weight reduction).

DEMONSTRATED CARDIOVASCULAR OUTCOMES

No increase in major adverse cardiovascular events
demonstrated with Ozempic® (estimated hazard ratio 0.74
[95% CI; 0.58-0.95]; actual risk reduction = 2.3%)1

January 4, 2018

In one large study looking at cardiovascular safety with Ozempic®, there was no increased risk for time to first major adverse cardiovascular event (MACE; components of MACE are cardiovascular death, non-fatal stroke, and non-fatal myocardial infarction) versus placebo.1

The SUSTAIN 6 trial was a 104-week, double-blind trial in which 3,297 patients with type 2 diabetes and high risk of cardiovascular events were randomized to Ozempic® 0.5 mg once weekly, Ozempic® 1 mg once weekly, or placebo in addition to standard of care. The primary objective of the trial was to confirm that treatment with Ozempic® does not result in any unacceptable increase in cardiovascular risk as compared to placebo in adults with type 2 diabetes. This was done by demonstrating that the upper limit of the two-sided 95% confidence interval (CI) of the hazard ratio for Ozempic® versus placebo is less than 1.8 when comparing time to first occurrence of a major adverse cardiovascular event.

There was no increased risk for MACE observed with Ozempic®. The estimated hazard ratio of MACE associated with Ozempic® relative to placebo was 0.74 with a 95% confidence interval of 0.58-0.95.1

OZEMPIC® IS AVAILABLE IN CANADA

A once weekly GLP-1 RA
treatment option in type 2 diabetes

January 4, 2018

Consider Ozempic® as an option for your type 2 diabetes patients.

Ozempic® is indicated for the once weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:1

  • diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance
  • metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control
  • metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control
  • basal insulin with metformin, when diet and exercise plus basal insulin with metformin do not achieve adequate glycemic control

Learn more about what Ozempic® can do for your patients in future articles.

Comparative clinical significance has not been established.
GLP-1=glucagon-like peptide-1; RA=receptor agonist

Resources

The latest Ozempic® Product Monograph

Download

Patient Diary

Download

Patient Brochure

Download

Dosing Poster

Download
References and Study Parameters Contact Us Disclaimer & Privacy